Treatment Refractory MAC Lung Disease clinical trials at UCSF

2 in progress, 1 open to eligible people

Treatment refractory MAC lung disease is a lung infection that does not get better with usual treatments. UCSF is running a study to test if an inhaled medicine called Clofazimine can help. This study looks at how safe and effective this new treatment is for patients.

Showing trials for

  • ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

    open to eligible people ages 18-85

    This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)

    Fresno, California and other locations

  • Epetraborole in Patients With Treatment-refractory MAC Lung Disease

    Sorry, in progress, not accepting new patients

    This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease. This study will enroll adult patients with treatment-refractory MAC lung disease who meet all eligibility criteria (including clinical, radiographic, and microbiological criteria).

    San Francisco, California and other locations

Our lead scientists for Treatment Refractory MAC Lung Disease research studies include .

Last updated: